NUVO Holdco Nuvo Group DG Ltd

SAN CARLOS, Calif., June 18 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (NASDAQ:NUVO) today announced that Dr. Ted W. Love, the company's chairman and chief executive officer, will present at the Jefferies 2nd Annual Healthcare Conference on Wednesday, June 25, 2008, at 1:30 p.m. ET in New York City. A live audio webcast of the presentation will be available online via the Investor Relations portion of Nuvelo's website at http://www.nuvelo.com/ or http://www.wsw.com/webcast/jeff26/nuvo. About Nuvelo Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. Information about Nuvelo is available at our website at http://www.nuvelo.com/ or by phoning 650-517-8000. DATASOURCE: Nuvelo, Inc. CONTACT: Lee Bendekgey, SVP, CFO and General Counsel of Nuvelo, Inc., +1-650-517-8358, ; or Nicole Foderaro of WeissComm Partners, +1-415-946-1058, , for Nuvelo, Inc. Web site: http://www.nuvelo.com/ http://www.wsw.com/webcast/jeff26/nuvo

Copyright